Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1

Rheumatology

Volumn 47, Issue 9, 2008, Pages 1335-1341

  Mozaffarian, Neely ^a,b   Wiedeman, A E ^b   Stevens, A M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Antigen presenting cell; Co stimulation; Human; Monocyte; Myeloid dendritic cell; Programmed death ligand 1; Systemic lupus erythematosus

Indexed keywords

CD14 ANTIGEN; GLYCOPROTEIN; PROGRAMMED DEATH LIGAND 1;

ADOLESCENT; ADULT; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; CELL ISOLATION; CELL LEVEL; CHILD; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE EXACERBATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKOCYTE; MALE; MONOCYTE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ADOLESCENT; ADULT; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; CELLS, CULTURED; CHILD; DENDRITIC CELLS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MONOCYTES; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 50849135184     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken256     Document Type: Article

References (51)

1. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
2. Keir ME, Liang SC, Guleria I et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006;203:883-95.
3. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007;8:239-45.
4. Kitazawa Y, Fujino M, Wang Q et al. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007;83:774-82.
5. Butte MJ, Keir ME, Pharnduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007;27:111-22.
6. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793-800.
7. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365-9.
8. Brown JA, Dorfman DM, Ma FR et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003;170:1257-66.
9. Kim HK, Guan H, Zu G et al. High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals. J Leukoc Biol 2006;79:686-95.
10. He FR, Zhu HF, Huang H et al. Programmed death-1 ligands-transfected dendritic cells loaded with glutamic, acid decarboxylase 65 (GAD65) inhibit both the alloresponse and the GAD65-reactive lymphocyte response. Clin Exp Immunol 2008;151:86-93.
11. Hirata S, Seniu S, Matsuyoshi H, Fukuma D, Uemura Y, Nishimura Y. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J Immunol 2005;174:1888-97.
12. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
13. Latchman YE, Liang SC, Wu Y et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 2004;101:10691-6.
14. Liang SC, Latchman YE, Buhlmann JE et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003;33:2706-16.
15. Martin-Orozco N, Wang YH, Yagita H, Dong C. Cutting edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ -T cell tolerance to tissue antigens. J Immunol 2006;177:8291-5.
16. Fife BT, Guleria I, Gubbels Bupp M et al. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 2006;203:2737-47.
17. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-8.
18. Zhu B, Guleria I, Khosroshahi A et al. Differential role of programmed death-ligand 1 and programmed death-ligand 2 in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol 2006; 176:3480-9.
19. Fukushima A, Yamaguchi T, Azuma M, Yagita H, Ueno H. Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice. Br J Ophthalmol 2006;90:1040-5.
20. Carter LL, Leach MW, Azoitei ML et al. PD-1/PD-L1, but not PD-1/ PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 2007;182:124-34.
21. Thorbum CM, Prokunina-Olsson L, Sterba KA et al. Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. Genes Immun 2007;8:279-87.
22. Prokunina L, Castillejo-Lopez C, Oberg F et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002;32:666-9.
23. Ferreiros-Vidal I, Gomez-Reino JJ Barros F et al. Association of PDCD1 with susceptibility to systemic lupus erythematosus: Evidence of population-specific effects. Arthritis Rheum 2004;50:2590-7.
24. Wang SC, Chen YJ, Ou TT et al. Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan. J Clin Immunol 2006;26:506-11.
25. Velazquez-Cruz R, Orozoo L, Espinosa-Rosales F et al. Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus. Eur J Hum Genet 2007;15:336-41.
26. Tsutsumi Y, Jie X, Ihara K et al. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with type 1 diabetes. Diabet Med 2006;23:1145-50.
27. Wang SC, Lin CH, Ou TT et al. Ligands for programmed cell death 1 gene in patients with systemic lupus erythematosus. J Rheumatol 2007;34:721-5.
28. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
29. Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000;9:445-50.
30. Yu HH, Wang LC, Lee JH, Lee CC, Yang YH, Chiang BL. Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients. Rheumatology 2007;46:1492-4.
31. Cherr DY, Hsieh TY, Hsieh CW, Lin FJ, Lan JL. Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still's disease. Arthritis Rheum 2007;57:1530-8.
32. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294:1540-3.
33. Feng X, Wu H, Grossman JM et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62.
34. Kami A, Abraham M, Monsonego A et al. Innate immunity in multiple sclerosis: Myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006;177:4196-202.
35. Robak E, Smolewski P, Wozniacka A, Sysa-Jedrzejowska A, Stepien H, Robak T. Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus. Eur Cytokine Netw 2004;15:222-30.
36. Liu MF, Li JS, Weng TH, Lei HY. Differential expression and modulation of costimulatory molecules CD80 and CD86 on monocytes from patients with systemic lupus erythematosus. Scand J Immunol 1999;49:82-7.
37. Decker P, Kotter I, Klein R, Berner B, Rammensee HG. Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology 2006;45:1087-95.
38. Scheinecker C, Machold KP, Majdic O, Hocker P, Knapp W, Smolen JS. Initiation of the autologous mixed lymphocyte reaction requires the expression of costimulatory molecules B7-1 and B7-2 on human peripheral blood dendritic cells. J Immunol 1998;161:3966-73.
39. Ding D, Mehta H, McCune WJ, Kaplan MJ. Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. J Immunol 2006; 177:5878-89.
40. Chen C, Qu QX, Huang JA et al. Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells. Immunobiology 2007;212:159-65.
41. Albert ML, Pearce SF, Francisco LM et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188:1359-68.
42. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PDA and CTLA-4. Nat Immunol 2005;6:280-6.
43. Sakane T, Steinberg AD, Green I. Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 1978;75:3464-8.
44. Fiore N, Castellano G, Blasi A et al. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol 2008;45:259-65.
45. Ding Q, Lu L, Wang B et al. B7H1-lg fusion protein activates the CD4+ IFN-gamma receptor+ type 1 T regulatory subset through IFN-gamma-secreting Th1 cells. J Immunol 2006;177:3606-14.
46. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007;178:2579-88.
47. Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2006;27:110-8.
48. Krishnan S, Kiang JG, Fisher CU et al. Increased caspase-3 expression and activity contribute to reduced CD3zeta expression in systemic lupus erythematosus T cells. J Immunol 2005;175:3417-23.
49. Geng L, Jiang G, Fang Y et al. B7-H1 expression is upregulated in peripheral blood CD14+ monocytes of patients with chronic hepatitis B virus infection, which correlates with higher serum IL-10 levels. J Viral Hepat 2006;13:725-33.
50. Trabattoni D, Saresella M, Biasin M et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 2003;101:2514-20.
51. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 2007;81:9249-58.